Alembic Pharmaceuticals Limited has successfully completed an unannounced onsite inspection conducted by the United States Food and Drug Administration (USFDA) at its Bioequivalence Facility in Vadodara, Gujarat.
The inspection was conducted from August 31 to September 10, 2026, as part of the USFDA's onsite assessment of the company's bioequivalence operations.
According to the company, the inspection was completed without any Form 483 observations. A Form 483 is issued by USFDA investigators when they identify conditions or practices that may indicate violations of regulatory requirements during an inspection.
The absence of Form 483 observations means that no objectionable conditions warranting inclusion in the inspectional observations were identified by the USFDA investigators during the inspection.
Alembic Pharmaceuticals informed the stock exchanges about the successful completion of the inspection, highlighting the outcome of the unannounced regulatory assessment at its Vadodara facility.
The Bioequivalence Facility supports studies that are important for demonstrating that a generic pharmaceutical product performs comparably to its corresponding reference product. Regulatory inspections of such facilities are an important part of ensuring compliance with applicable quality, data integrity and study-related requirements.
The successful completion of the USFDA inspection with no Form 483 observations represents a positive regulatory outcome for Alembic Pharmaceuticals and its bioequivalence operations in Vadodara.
